Best Pharma Manufacturing Podcasts (2024)

1
Vertex submits NDA for CF drug, MacroGenics reports ADC prostate cancer trial patient deaths, FTC extends review of Novo-Catalent deal [The good, the bad, the ugly] 4:14

4h ago4:14

4:14

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Vertex submits NDA for CF drug The bad — MacroGenics reports patient deaths in prostate cancer ADC trial The ugly — FTC extends review of Novo-Catalent deal…

1
Advancements in cell & gene therapy manufacturing (Part II) 31:23

3h ago31:23

31:23

This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. In this episode, Fierce Pharma’s Fraiser Kansteiner interviews Delara Motlagh, head of cell therapy at Catalent; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle…

1
New Frontiers in Epilepsy and Seizure Treatments ft. Dr. Jeremy Levin and Meg Alexander, Ovid Therapeutics 47:51

1h ago47:51

47:51

In this episode, Ayesha spoke with Jeremy Levin, D. Phil, MB BChir, CEO and Chairman of Ovid Therapeutics Inc., and Meg Alexander, Chief Strategy Officer at Ovid. Ovid Therapeutics is a biopharmaceutical company focused on the development of medicines for epilepsies and seizure-related neurological disorders. Prior to founding Ovid, Dr. Levin was p…

1
Quick Hits: Leveraging AI to Drive Better Conversations with Patients 11:48

3h ago11:48

11:48

In this Quick Hits House Call, Dave talks to Cain Brothers’ Managing Director Jill Frew about the exciting potential of AI-powered tools to derive insights from physician-patient communications and reduce the burden of documentation, paving the way for more personalized care and greater administrative efficiency. Cain Brothers is a division of KeyB…

1
Fulfilling the promise of cell & gene therapies through manufacturing (Part I) 29:15

1h ago29:15

29:15

This week’s episode of “The Top Line,” kicks off a series diving into the latest advancements in cell and gene therapy manufacturing. In this episode, Fierce Pharma’s Fraiser Kansteiner sits down with Ori Biotech CEO Jason Foster and the Cell Therapy Manufacturing Center's CEO, Jason Bock. They delve into the current state of cell and gene therapy …

1
Quick Hits: The Intersection of Ambulatory Care, Health Systems, and Private Equity 12:31

15h ago12:31

12:31

In this Quick Hits House Calls, Dave talks to Cain Brothers’ Managing Director Dave Morlock about health system turmoil and transformation, the role of private equity, and the upcoming Cain Brothers’ Health System and Private Equity Collaboration Conference on June 12-13 in Nashville. Cain Brothers is a division of KeyBanc Capital Markets.…

1
The State of Infectious Diseases and New Trivalent Flu Vaccine ft. Infectious Disease Experts Dr. William Schaffner and Dr. Kelly Moore 48:51

7d ago48:51

48:51

In this episode, Ayesha spoke with William Schaffner, MD, Professor of Preventive Medicine Health Policy and Professor in the Division of Infectious Diseases at Vanderbilt University; and Kelly Moore, MD, MPH, President and CEO at Immunize.org and Associate Professor of Health Policy at Vanderbilt University. Dr. Schaffner and Dr. Moore discussed t…

1
Neurocrine wins FDA nod for 'sprinkle' Ingrezza, Moderna-Metagenomi deal ends, Emergent's layoffs [The good, the bad, the ugly] 3:37

8d ago3:37

3:37

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Neurocrine wins FDA nod for 'sprinkle' Ingrezza formulation The bad — Moderna, Metagenomi end gene editing collab The ugly — Emergent announces layoffs, closes sites…

1
A closer look at 2023's top biopharma deals and what lies ahead 18:07

3d ago18:07

18:07

This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year. Fierce Pharma Senior Writer Kevin Dunleavy sits down with Cody Powers, a consultant who advises companies on business development and franchise growth strategy, to discuss the reasons behind the n…

1
Delivering Exceptional Clinical Trial Experiences for Patients 39:00

4d ago39:00

39:00

For more information, visit DPHARMconference.com.By Pharma Talk Radio

1
Optimizing the Integration of Mobile and Patient-Facing Tech in Clinical Trials 37:00

16d ago37:00

37:00

For more information, visit patientsaspartners.org.By Pharma Talk Radio

1
Psychedelic-Based Therapeutics for Generalized Anxiety Disorder (GAD) – Interview with Robert Barrow, CEO, MindMed 26:04

5d ago26:04

26:04

In this episode, Ayesha spoke with Robert Barrow, CEO and Board Director at MindMed, a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The company is developing innovative psychedelic-based product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways…

1
ctDNA Potential for Prognostic Stratification, Tumor Insights & Drug Development 42:00

5d ago42:00

42:00

For more information, visit IO360summit.com.By Pharma Talk Radio

1
Novartis wins rare cancer pediatric indication, BMS layoffs, McKinsey under fire [The good, the bad, the ugly] 4:26

6d ago4:26

4:26

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Novartis wins rare cancer pediatric indication for Lutathera The bad — BMS unveils cost-saving initiative, layoffs The ugly — McKinsey under fire for alleged role in opioid crisis…

1
A look at pharma revenue rankings 10:28

14d ago10:28

10:28

Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. The most recent edition, published this month, ranks each pharma based on their total revenues for 2023. This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Senior Writer Kevin Dunleavy break down the numbers, highlight k…

1
Developing Conditionally Active Antibodies: Interview with John K. Celebi, President & CEO, Sensei Bio. 28:16

24d ago28:16

28:16

In this episode, Ayesha spoke with John K. Celebi, MBA, President & Chief Executive Officer, Sensei Bio, a clinical-stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Sensei Biotherapeutics specializes in creating conditionally active antibodies. These are engineered to operat…

1
What to Expect at the 2024 Patients as Partners EU Conference 7:00

22d ago7:00

7:00

Valerie Bowling, Executive Director of the Conference Forum, discusses what attendees can expect at the 8th annual Patients as Partners EU conference, including keynotes, key topics, and the wide breadth of pharma companies present. For more information about the upcoming event, full agenda and speakers, visit https://patientsaspartnerseu.com/…

1
GSK antibiotic hits phase 3 goals, Genentech-Adaptimmune collab ends, Par Pharma recall [The good, the bad, the ugly] 4:10

25d ago4:10

4:10

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — GSK antibiotic hits phase 3 goals in gonorrhea The bad — Genentech ends $3B Adaptimmune T-cell collab The ugly — Par Pharmaceutical recalls Treprostinil injection for potential contamination…

1
BMS schizophrenia drug shines, Novartis axes jobs, Lilly compounding suit dismissed [The good, the bad, the ugly] 5:01

17d ago5:01

5:01

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — BMS schizophrenia drug shines in phase 3 trial The bad — Novartis to axe 680 jobs The ugly — Lilly compounding suit dismissedBy Pharma Manufacturing

1
Winning formulas for the best biotech and drug names 14:30

17d ago14:30

14:30

This week on “The Top Line,” we're joined by Fierce Biotech Senior Editor Annalee Armstrong and Fierce Pharma Marketing Senior Editor Ben Adams. We're diving into our recent spin on March Madness at Fierce. This time around, Fierce Biotech kicked off its inaugural Best Biotech Name tournament, while over at Fierce Pharma Marketing, we held our bian…

1
Treg Cell Therapy for Neurodegenerative Diseases – Interview with Dr. Howard Berman, CEO, Coya Therapeutics 34:02

27d ago34:02

34:02

In this episode, Ayesha spoke with Howard Berman, PhD, Founder and CEO of Coya Therapeutics, a clinical-stage biotech company developing regulatory T cell (Treg) therapies targeting neurodegenerative, autoimmune and metabolic diseases. Dr. Berman founded Coya Therapeutics in 2021. Dr. Berman has over 18 years of entrepreneurial and industry experie…

1
[Sponsored] What does the future of specialist distribution look like? 11:34

1M ago11:34

11:34

Jeff Beck of BioCare is in the hotseat for this edition of The Top Line. Beck is the Chief Development Officer at the company, which stands tall as a pioneer in specialty product distribution with over 40 years of experience dating back to hemophilia therapies. During the conversation, Beck provides an inside look at the rapidly evolving specialty …

1
2024 election's impact on manufacturing 32:57

24d ago32:57

32:57

Politics, whether we like them or not, weigh heavy on manufacturing’s future. In case you haven’t heard, it is an election year! Which means, global trade, regulations, immigration, national security and taxation will all be part of the national discourse, and all of those topics touch on manufacturing in one way or another. During this podcast, we…

1
Deep dive: Biopharma layoffs in Q1 17:47

24d ago17:47

17:47

This week on "The Top Line," we explore biopharma layoffs in the first quarter of 2024. Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. With a notable number of layoff rounds marking the start of the year, they examine the f…

1
Taking Lessons from Manufacturing Immunotherapies to Accelerate Development 44:00

1M ago44:00

44:00

For more information, visit IO360summit.com.By Pharma Talk Radio

1
Improving Cancer Screening Among Métis Communities: Interview with Margaret Froh, President, Métis Nation of Ontario 32:08

26d ago32:08

32:08

In this episode, Ayesha spoke with Margaret Froh, President of the Métis Nation of Ontario (MNO). Margaret is also a lawyer by training. The Métis are a distinct Indigenous people recognized in s.35 of Canada’s Constitution. Métis communities have their own shared customs, traditions and collective identities that are rooted in kinship, their speci…

1
Basilea grabs FDA nod, Verve halts gene editing trial, Amylyx pulls ALS drug [The good, the bad, the ugly] 3:47

1M ago3:47

3:47

Editor's Review: Week of April 1 Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Basilea Pharmaceutica receives FDA approval for its IV antibiotic The bad — Verve Therapeutics halts gene editing trial, again The ugly — Amylyx removes ALS treatment…

1
Enhancing Solubility with Novel Excipient Technologies 31:00

1M ago31:00

31:00

As new drugs in development have poorer solubility and bioavailability, there is a need for novel solubility enhancing polymers to improve drug loading and improve patient adherence. In this podcast, Nick DiFranco explains some of the shortcomings of traditional solubility enhancers as well as key considerations for novel technologies. Nick also pr…

1
The unrecognized threat of PAD 14:12

1M ago14:12

14:12

This week on “The Top Line,” we explore peripheral arterial disease, a serious health issue that is often overlooked and undermanaged. Join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of the Peripheral Vascular Intervention & CLI Program at Rush University Medical Center.…

1
Quick Hits: A Ground-Breaking Transaction 11:54

1M ago11:54

11:54

In this Quick Hits House Calls, Dave talks to Cain Brothers’ Director Andy Labovitz about General Catalyst’s proposed acquisition of Summa Health – and whether that transaction represents the future for more health systems around the country. Cain Brothers is a division of KeyBanc Capital Markets.By Cain Brothers, a division of KeyBanc Capital Markets

1
Cell Therapies for Chronic Kidney Disease: Featuring Bruce Culleton, CEO, ProKidney 25:41

1M ago25:41

25:41

This episode features an interview with Bruce Culleton, MD, CEO, ProKidney, a late clinical-stage biotech company focused on the development of a pioneering cell therapy candidate that aims to transform the treatment landscape for chronic kidney disease. Prior to joining ProKidney in 2023, Dr. Culleton served as Vice President and General Manager a…

1
Measuring the Value of DCTs and Hybrid Models 32:00

1M ago32:00

32:00

For more information, visit DPHARMconference.com.By Pharma Talk Radio

1
[The good, the bad, the ugly] Editor's Review week of March 25 3:45

1M ago3:45

3:45

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Akebia Therapeutics' Vafseo anemia drug The bad — Bristol Myers Squibb's Crohn's disease drug disappoints The ugly — FDA rejects Regeneron Pharmaceuticals lymphoma treatment…

1
The top money raisers in biotech 18:55

1M ago18:55

18:55

This week on "The Top Line," we explore our annual special report on the top money raisers in the biotech industry. Which company raised the most funding in 2023? What does the biotech financing landscape look like for this year? Fierce Biotech's Annalee Armstrong and Max Bayer answer those questions and many more in today's episode. They also disc…

1
Navigating and Adopting Innovation in a Post- Pandemic World 26:00

1M ago26:00

26:00

For more information, visit DPHARMconference.com.By Pharma Talk Radio

1
Tackling Diabetic Kidney Disease: Featuring Robert Perkins, VP, US Medical Affairs (Renal), Bayer 18:06

1M ago18:06

18:06

In marking National Kidney Month, this episode features an interview with Robert Perkins, MD, Vice President, US Medical Affairs (Renal) at Bayer who spoke about kidney health and diabetes-inflicted chronic kidney disease. National Kidney Month is observed every March in the US to raise awareness about kidney health and promote preventive action. I…

1
[The good, the bad, the ugly] Editor's Review week of March 18 5:31

1M ago5:31

5:31

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Orchard gene therapy wins first FDA nod for rare pediatric disease The bad — Abiomed recalls heart pump instructions due to perforation risks The ugly — J&J files lawsuit against a former employee fo…

1
A closer look at European biotech investment in 2024 18:28

1M ago18:28

18:28

This week on “The Top Line,” we explore the European biotech investment landscape. Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. To learn more about the topics in this episode: 'The fundamentals are really str…

1
People in Life Sciences Series: Day-in-the-Life of a Pharmacovigilance Professional – Interview with Ashish Jain, Senior Director of Clinical Safety and PV, Curis 34:04

2M ago34:04

34:04

In this featured episode of Xtalks People in Life Sciences, Ayesha spoke with Ashish Jain, Senior Director of Clinical Safety and Pharmacovigilance (PV) at Curis, a pioneering biotech company specializing in cutting-edge cancer therapies. Jain shared his journey into clinical safety and PV, highlighting key milestones along the way. Delving into hi…

1
Quick Hits: The Case for Additional Partnership Between Skilled Nursing and Acute Care Providers 10:16

2M ago10:16

10:16

In this Quick Hits House Calls, Dave talks to Cain Brothers’ Director Dom Porretta about the intense pressure on skilled nursing facilities and health systems and the need for fresh thinking on joint ventures that reduce discharge bottlenecks and improve day-to-day operations and overall care quality. Cain Brothers is a division of KeyBanc Capital …

1
[The good, the bad, the ugly] Editor's Review week of March 11 3:54

2M ago3:54

3:54

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Madrigal wins first FDA nod for NASH The bad — Acadia abandons plans to expand pimavanserin indications The ugly — BIO backs BIOSECURE Act, boots WuXi…

1
Inclusivity in psoriasis trials with Takeda 14:45

2M ago14:45

14:45

This week on “The Top Line,” we’re diving into the topic of diversity in clinical trials, examining both the progress made and the ongoing work needed to ensure inclusivity. In this episode, Fierce Biotech Senior Editor Annalee Armstrong engages in a conversation with Karen Correa, Ph.D., Head of Global Clinical Operations at Takeda and Executive S…

1
Turning a Search for Lung Cancer Biomarkers into a Patient Empowerment Community 21:00

2M ago21:00

21:00

Summary: In this podcast, Terri Conneran tells the story of how her cancer diagnosis and a search for relevant biomarkers turned into KRAS Kickers, a cancer research advocate community. For more information on PharmaTalk Radio podcasts, visit theconferenceforum.org.By Pharma Talk Radio

1
Building Cancer Awareness and Empowering Métis Youth: Featuring Jordyn Playne, President, Métis Nation of Ontario Youth Council 19:24

2M ago19:24

19:24

In this episode, Ayesha spoke with Jordyn Playne, President of the Métis Nation of Ontario Youth Council, a group of youth representatives from across Ontario who advocate on behalf of the concerns and interests of Métis youth at the provincial level. Jordyn is also a Clinical Consultant and Trainer at Waypoint Centre for Mental Health Care, as wel…

1
Engaging All Stakeholders for Clinical Trial Patient Engagement and Value 54:00

2M ago54:00

54:00

For more information, visit theconferenceforum.org.By Pharma Talk Radio

1
[The good, the bad, the ugly] Editor's Review week of March 4 4:16

2M ago4:16

4:16

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Boehringer Ingelheim to cap out-of-pocket inhaler prices The bad — Amylyx ALS drug falls short in phase 3 trial The ugly — FDA delays Eli Lilly Alzheimer's drug decision with last-minute AdComm…

1
Quick Hits: New Initiatives from CMS to Improve Access to Behavioral Health Services  7:32

2M ago7:32

7:32

In this Quick Hits House Calls, Dave talks to Cain Brothers’ Managing Director Erika Haanpaa about exciting new developments in access to behavioral health care. Cain Brothers is a division of KeyBanc Capital Markets.By Cain Brothers, a division of KeyBanc Capital Markets

1
Fierce Medtech's Fierce 15 16:20

2M ago16:20

16:20

In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15. To learn more about the topics in this episode: Fierce Medtech's Fierce 15 of 2023 See omnystudio.com/listener for privacy informati…

1
Transforming Eye Care: Innovating New Glaucoma and Dry Eye Disease Treatments 23:37

2M ago23:37

23:37

In this episode, Ayesha spoke with H. B. Pierre Simon Jr., MBA, Vice President, Global Head of Marketing, Sight Sciences, about the evolving field of eye care. Sight Sciences is focused on developing and commercializing innovative solutions for eye diseases like glaucoma and dry eye disease to transform care and improve patients’ lives. Among some …

1
[The good, the bad, the ugly] Editor's Review week of February 29 3:07

3M ago3:07

3:07

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Iovance has launches Amtagvi The bad — FDA rejected Theratechnologies HIV instramuscular injection The ugly — BioMarin receives a subpoena from the DOJ…

Podcasts Worth a Listen

Pharma Manufacturing Podcasts

Podcasts Worth a Listen

Quick Reference Guide